PAUL JUTTE: Open Payments
NPI 1114540317 · MIAMISBURG, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$818 in 44 payments from 15 companies in 2025. Trend: 2023 $688 · 2024 $600 · 2025 $818
Food & beverage: $818
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 14 | $283 |
| Alkermes, Inc. | 6 | $112 |
| Vanda Pharmaceuticals Inc. | 4 | $68 |
| Neurocrine BioSciences, Inc. | 3 | $66 |
| Almatica Pharma LLC | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 4 | $60 |
| Lundbeck LLC | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
Products named: Auvelity, ARISTADA, INGREZZA, LOREEV XR, REXULTI, HETLIOZ, ABILIFY MAINTENA, LYBALVI.
Industry payments across OH — which companies pay providers there.
